JO3062B1 - R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري - Google Patents

R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري

Info

Publication number
JO3062B1
JO3062B1 JOP/2011/0294A JOP20110294A JO3062B1 JO 3062 B1 JO3062 B1 JO 3062B1 JO P20110294 A JOP20110294 A JO P20110294A JO 3062 B1 JO3062 B1 JO 3062B1
Authority
JO
Jordan
Prior art keywords
pyrazol
ethoxy
crystalline
ethanol
dichloropyridin
Prior art date
Application number
JOP/2011/0294A
Other languages
English (en)
Inventor
Alan Diseroad Benjamin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44999860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3062(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3062B1 publication Critical patent/JO3062B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يوفر الاختراع الحالي (R)-(E)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1H-إندازول-3-يل)?ينيل)-1H-بيرازول-1-يل)إيثانول بلوري الذي يكون مفيدًا في علاج السرطان.
JOP/2011/0294A 2010-10-05 2011-09-22 R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري JO3062B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38991110P 2010-10-05 2010-10-05

Publications (1)

Publication Number Publication Date
JO3062B1 true JO3062B1 (ar) 2017-03-15

Family

ID=44999860

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0294A JO3062B1 (ar) 2010-10-05 2011-09-22 R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري

Country Status (35)

Country Link
US (1) US8530665B2 (ar)
EP (1) EP2625175B1 (ar)
JP (1) JP5940547B2 (ar)
KR (1) KR101527661B1 (ar)
CN (1) CN103153983B (ar)
AR (1) AR083091A1 (ar)
AU (1) AU2011312485B2 (ar)
BR (1) BR112013006336A2 (ar)
CA (1) CA2813329C (ar)
CL (1) CL2013000884A1 (ar)
CO (1) CO6710911A2 (ar)
DK (1) DK2625175T3 (ar)
DO (1) DOP2013000072A (ar)
EA (1) EA021817B1 (ar)
EC (1) ECSP13012539A (ar)
ES (1) ES2558777T3 (ar)
HR (1) HRP20151299T1 (ar)
HU (1) HUE026379T2 (ar)
IL (1) IL224850A (ar)
JO (1) JO3062B1 (ar)
MA (1) MA34552B1 (ar)
ME (1) ME02307B (ar)
MX (1) MX2013003907A (ar)
NZ (1) NZ608482A (ar)
PE (1) PE20140252A1 (ar)
PH (1) PH12013500649A1 (ar)
PL (1) PL2625175T3 (ar)
PT (1) PT2625175E (ar)
RS (1) RS54457B1 (ar)
SG (1) SG188286A1 (ar)
SI (1) SI2625175T1 (ar)
TW (1) TWI418554B (ar)
UA (1) UA111725C2 (ar)
WO (1) WO2012047699A1 (ar)
ZA (1) ZA201301560B (ar)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
CN103819396B (zh) * 2014-02-26 2016-06-15 四川大学 一种手性的1-（3,5-二氯吡啶-4-基）-乙醇的合成方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
ES3061844T3 (en) 2018-05-04 2026-04-07 Incyte Corp Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111705099B (zh) * 2020-07-01 2022-03-08 天津药明康德新药开发有限公司 一种(s)-1-(3,5-二氯吡啶-4-取代)乙醇的制备方法
CN116635076A (zh) * 2020-12-17 2023-08-22 荣山医药股份有限公司 大环化合物及其用途
IL303419A (en) * 2020-12-17 2023-08-01 Blossomhill Therapeutics Inc Macrocyclic compounds and their use
CR20230325A (es) * 2020-12-30 2023-12-11 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
JP4361727B2 (ja) 2000-09-11 2009-11-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド チロシンキナーゼインヒビターとしてのキノリノン誘導体
KR20050004214A (ko) 2002-05-31 2005-01-12 에자이 가부시키가이샤 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
EP1745035A1 (en) * 2004-03-17 2007-01-24 Pfizer Inc. Polymorphic and amorphous forms of 2,5-dimethyl-2h-pyrazole-3-carboxylic acid-{2-fluoro-5-¬3-((e)-2-pyridin-2-ylvinyl)-1h-indazol-6-ylamino|-phenyl}-amide
JP4746299B2 (ja) * 2004-07-16 2011-08-10 ジュズ インターナショナル ピーティーイー エルティーディー 金属酸化物粉末の製造方法
JP2006163651A (ja) 2004-12-03 2006-06-22 Sony Computer Entertainment Inc 表示装置、表示装置の制御方法、プログラム及びフォントデータ
US20060160863A1 (en) * 2005-01-05 2006-07-20 Agouron Pharmaceuticals, Inc. Polymorphic and amorphous forms of 2-{3-[(E)-2-(4,6-dimethyl-pyridin-2-yl)-vinyl]-1H-indazol-6-ylamino}-N-(4-hydroxy-but-2-ynyl)benzamide
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
EP4249063A3 (en) * 2007-04-05 2024-03-13 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
AR078411A1 (es) * 2009-05-07 2011-11-09 Lilly Co Eli Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende

Also Published As

Publication number Publication date
ECSP13012539A (es) 2013-06-28
JP2013538875A (ja) 2013-10-17
CN103153983A (zh) 2013-06-12
PL2625175T3 (pl) 2016-04-29
MX2013003907A (es) 2013-06-03
BR112013006336A2 (pt) 2019-09-24
US8530665B2 (en) 2013-09-10
AR083091A1 (es) 2013-01-30
UA111725C2 (uk) 2016-06-10
EP2625175A1 (en) 2013-08-14
JP5940547B2 (ja) 2016-06-29
PT2625175E (pt) 2016-01-22
TWI418554B (zh) 2013-12-11
CN103153983B (zh) 2014-11-05
HRP20151299T1 (hr) 2016-01-01
EA201390275A1 (ru) 2013-07-30
US20120083511A1 (en) 2012-04-05
WO2012047699A1 (en) 2012-04-12
NZ608482A (en) 2014-03-28
PE20140252A1 (es) 2014-03-12
AU2011312485B2 (en) 2014-09-04
TW201249826A (en) 2012-12-16
DOP2013000072A (es) 2013-08-15
SI2625175T1 (sl) 2016-01-29
ME02307B (me) 2016-06-20
KR20130052680A (ko) 2013-05-22
ZA201301560B (en) 2014-08-27
EP2625175B1 (en) 2015-11-18
CL2013000884A1 (es) 2013-10-18
CA2813329C (en) 2015-05-26
ES2558777T3 (es) 2016-02-08
DK2625175T3 (en) 2016-02-01
PH12013500649A1 (en) 2013-05-06
HK1184147A1 (zh) 2014-01-17
KR101527661B1 (ko) 2015-06-09
SG188286A1 (en) 2013-04-30
IL224850A (en) 2016-09-29
CO6710911A2 (es) 2013-07-15
EA021817B1 (ru) 2015-09-30
RS54457B1 (sr) 2016-06-30
AU2011312485A1 (en) 2013-03-07
CA2813329A1 (en) 2012-04-12
HUE026379T2 (en) 2016-06-28
MA34552B1 (fr) 2013-09-02

Similar Documents

Publication Publication Date Title
EA201390275A1 (ru) Кристаллический (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпиридин-4-ил)этокси)-1h-индазол-3-ил)винил)-1h-пиразол-1-ил)этанол
CO6450624A2 (es) Compuestos vinil indazolilo
UA122520C2 (uk) Кристалічна форма 2-[4-(4-хлорфенокси)-2-(трифторметил)феніл]-1-(1,2,4-триазол-1-іл)пропан-2-олу, агрохімічна композиція, застосування та спосіб боротьби зі шкідливими грибами
DK3154959T3 (da) 1-((3s,4r)-4-(3-fluorphenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urinstof som en trka-kinaseinhibitor
ZA201100026B (en) 4-(pyridin-4-yl)-1h-(1,3,5)triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
UY34202A (es) Compuestos fungicidas 2-(2-clor0-4-(4-cloro-fenoxi)-fenil]-1-(1,2,4]triazol-1-1l-etanol alquilo sustituidos
ME03556B (me) 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1 h-pirazol-1-il]oktan- ili нертan - niтril kао јак inhibiтori
NZ627113A (en) Substituted pyrimidine compounds and their use as syk inhibitors
CY1120454T1 (el) Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος
DK2878598T3 (da) Krystallinsk form af 4-[5-(pyridin-4-yl)-1h-1,2,4-triazol-3-yl]pyridin-2-carbonitril
SI2632921T1 (sl) Polimorfi in soli 6-(1H- indol-4-il)-4-(5-((4-(1-metiletil)-1-piperazinil)metil)-1,3-oksazol-2- il)-1H-indazola kot inhibitorji PI3K za uporabo pri zdravljenju npr. respiratornih motenj
MX385586B (es) Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia.
CL2018003107A1 (es) Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
ECSP099673A (es) Formas sólidas de un inhibidor de cinasa raf
EA201400001A1 (ru) Новые производные фталазинонпирролопиримидинкарбоксамида
IL239928B (en) Compositions comprising (s)-1-(4-(3,4-dichlorophenyl)piperidino)-3-(2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy)-2-propanol for treating depression
NZ716494A (en) Processes and intermediates for the preparation of a pde10 inhibitor
EP3541797A4 (en) 4 - ((6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H
TN2013000142A1 (en) Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor
CY1117146T1 (el) Κρυσταλλικη (r)-(ε)-2-(4-(2-(5-(1-(3,5-διχλωροπυριδινο-4-υλ)αιθοξυ)-1 η-ινδαζολο-3-υλ)βινυλο)-1 η-πυραζολο-1-υλ)αιθανολη και η χρηση της ως αναστολεα του fgfr
BRPI0816757A2 (pt) Formas polimorfas de (s) -2- ((4-benzofuranil) carbonilaminometil)-1-((4-(2-metil-5-(4-fluorofenil))tia zolil)carbonil) piperidina
TH132151A (th) ((r)-(e)-2-(4-(2-(5-(1-(3,5-ไดคลอโรไพริดิน-4-อิล)เอทธอกซี)-1h-อินดาซอล-3-อิล)ไวนิล)-1h-ไพราซอล-1-อิล)เอทธานอลเชิงผลึก
TH115254A (th) สารประกอบไวนิลอินดาโซลอิล
UA114081U (uk) 5-(2-(4-(диметиламіно)бензиліден)гідразиніл)-4-феніл-4h-1,2,4-триазол-3-тіолу гідрохлорид, що стимулює ріст пшениці озимої